Say goodbye to AbbVie's ever-growing Humira sales: The biosim decline has officially begun

AbbVie's Humira just posted its first-ever drop in worldwide sales—and with biosimilars on the march in Europe, it's not likely to be the last. Make no mistake; AbbVie is still making a fortune off the mega blockbuster immunology med. In the first quarter, worldwide Humira sales may have slipped 5.6%, but that's still $4.46 billion. And in the U.S., revenue's still growing. Stateside sales increased by 7% to $3.22 billion. But bossism hasn’t hit in the U.S. yet. And take a look what's happened outside the U.S. after European biosim launches in October last year. AbbVie reported that its key money maker fell 27.9% outside its home country, to $1.23 billion.

Spotlight

Spotlight

Related News